THYMOPOIETIN PENTAPEPTIDE TREATMENT OF PRIMARY IMMUNODEFICIENCIES

F. Aiuti, M. Fiorilli, I. Quinti, R. Seminara, L. Businco, E. Galli, P. Rossi, G. Goldstein

Research output: Contribution to journalArticlepeer-review

Abstract

26 patients with primary immunodeficiencies (3 infants with severe combined immunodeficiency [SCID] 3 with DiGeorge syndrome, 6 with T-cell defect or SCID with B cells, 4 with common variable hypogammaglobulinaemia and associated T-cell defect, 5 with ataxia-telangiectasia, and 5 with hyper-IgE syndrome) were treated with thymopoietin pentapeptide (TP-5) at a dose of 0·5 mg/kg daily for 2 weeks and then 3 times a week at 0·5 mg/kg for 10 weeks. 3 patients with DiGeorge syndrome and 3 with primary T-cell defect demonstrated pronounced clinical and immunological improvement during treatment. None of the patients with SCID and 3 of 6 patients with SCID with B cells or primary T-cell defect showed any clinical or immunological changes during therapy. In 5 patients with ataxia-telangiectasia clinical manifestations and immunological tests were unchanged by TP-5. Abnormality of T cells in cases of hyper-IgE syndrome was not corrected by TP-5 treatment.

Original languageEnglish
Pages (from-to)551-555
Number of pages5
JournalLancet
Volume321
Issue number8324
DOIs
Publication statusPublished - Mar 12 1983

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'THYMOPOIETIN PENTAPEPTIDE TREATMENT OF PRIMARY IMMUNODEFICIENCIES'. Together they form a unique fingerprint.

Cite this